)
)
)
Gut-Brain Axis Therapeutics
Gut-Brain Axis Therapeutics (GBAT) is a U.S. clinical-stage biotech developing microbiome-based therapies for neurodevelopmental disorders, including Autism Spectrum Disorder (ASD) and Pitt-Hopkins Syndrome (PTHS).
Its proprietary Microbiota Transplant Therapy (MTT) replaces a patient’s dysfunctional gut microbiome with a healthy donor’s, restoring gut-brain balance.
In the Phase 1, open-label study that included 18 children with ASD, prior to MTT treatment, 83% of the participants were rated as having severe autism.
Two years post-treatment, only 17% remained severe, while 44% fell below the diagnostic threshold for ASD.
Phase 2 results confirmed significant, durable improvements and strong safety. Spun out of Arizona State University, GBAT holds OD and Pediatric Rare Disease designations for PTHS, accelerating its FDA path with estimated approval in 2027.
We are currently raising a $20M Series A to support its pivotal Phase 3 trial in ASD and scale-up of its manufacturing capabilities.
Address
TempeArizona
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)